Regardless of the precise signalling networks orchestrating the observed biological responses, these data demonstrate that therapeutic targeting of TWEAK/Fn14 signalling is not only a promising avenue to potentially inhibit liver disease progression, but may be equally warranted in the chronic pancreatitis setting. Here, TNFSF12 is linked to liver disorder.